阿姆布里森坦作为单疗法和与塔达拉菲尔联合使用对大鼠糖尿病勃起功能障碍的潜在影响
Omnia Azmy Nabeh1, Fatma Ahmed El-Batrawy1, Omayma Anwar Khorshid1
1Medical Pharmacology, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Urologia
|August 29, 2023
概括
安布里森坦是一种选择性内分泌素A型受体阻塞剂,有效地改善了大鼠糖尿病勃起功能障碍. 这项研究表明,安布里森坦在治疗糖尿病引起的勃起功能障碍方面具有与塔达拉菲尔相当的治疗潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病勃起功能障碍 (ED) 是糖尿病的一个常见并发症.
- 选择性内甲素A型受体 (ETAR) 阻断剂代表了ED的潜在治疗途径.
研究的目的:
- 在小鼠糖尿病性ED的实验模型中研究安布里森坦的疗效.
- 为了比较ambrisentan与tadalafil及其组合疗法的效果.
主要方法:
- 成年雄性Sprague Albino大鼠被随机分配到对照组,安布里森坦,塔达拉菲尔或糖尿病组.
- 通过使用链毒素诱导糖尿病,大鼠接受安布里森坦,塔达拉菲尔或其组合4周.
- 评估包括交配行为,洞内压力 (ICP) 测量和生物化学分析.
主要成果:
- 安布里森坦和塔达拉菲尔都改善了糖尿病大鼠的血糖控制,胰岛素敏感性,水平和氧化水平.
- 安布里森坦增强了ICP和配对指数,具有可容忍的缩血压 (SBP).
- 联合安布里森坦/塔达拉菲尔治疗导致SBP恶化,并恶化了ICP和交配指数.
结论:
- 安布里森坦在预防和改善大鼠糖尿病性勃起障碍方面显示出显著的治疗潜力.
- 它的疗效与tadalafil可比,这表明它是一种可行的替代治疗选择.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
610
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
221
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
186
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
186
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
200
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
200